Page 30 - CBAC Newsletter 2016

Reference List

204. (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]
diazepin-3-yl]acetamide. J Med Chem. 40, 3865-3868
205. Towart R, Linders JT, Hermans AN, Rohrbacher J, van der Linde HJ, Ercken M, Cik M, Roevens P, Teisman A,
Gallacher DJ. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug
206. safety screening? J Pharmacol Toxicol Methods. 60, 1-10, 2009.
207. Whitworth CA, Rybak LP, Kemp R, Spence S. Pharmacological antagonism of the slow-activating delayed
208. rectifying potassium channel (I(Ks)) has no effect on cochlear structure and function in vivo.
209. Pharmacol Toxicol. 88, 45-50, 2001.
210. Hartmann R, Gerlach U, Klinke R. Ototoxic side-effects of the I(Ks)-channel blocker HMR1556.
211. Hear Res. 172, 145-150, 2002.
212. Morokuma J, Blackiston D, Levin M. KCNQ1 and KCNE1 K+ channel components are involved in early
left-right patterning in Xenopus laevis embryos. Cell Physiol Biochem. 21, 357-372, 2008.
213. Manikkam M, Li Y, Mitchell, BM, Mason DE, Freeman LC. Potassium channel antagonists influence porcine
214. granulosa cell proliferation, differentiation, and apoptosis. Biol Reprod. 67, 88-98, 2002.
215. Mason DE, Mitchell KE, Li Y, Finley MR, Freeman LC. Molecular basis of voltage-dependent potassium
216. currents in porcine granulosa cells. Mol Pharmacol. 61, 201-213, 2002.
Seebohm G, Chen J, Strutz N, Culberson C, Lerche C, Sanguinetti MC. Molecular determinants of KCNQ1
channel block by a benzodiazepine. Mol Pharmacol. 64, 70-77, 2003.
Yang WP, Levesque PC, Little WA, Conder ML, Shalaby FY, Blanar MA. KvLQT1, a voltage-gated potassium
channel responsible for human cardiac arrhythmias. Proc Natl Acad Sci USA. 94, 4017-4021, 1997.
Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action. Mechanism of
potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation.
82, 2235-2242, 1990.
Arena JP, Kass RS. Block of heart potassium channels by clofilium and its tertiary analogs: relationship
between drug structure and type of channel blocked. Mol Pharmacol. 34, 60-66, 1998.
Jepps TA, Olesen SP, Greenwood IA. One man's side effect is another man's therapeutic opportunity:
targeting Kv7 channels in smooth muscle disorders. Br J Pharmacol. 168, 19-27, 2013.
Long SB, Tao X, Campbell EB, MacKinnon R. Atomic structure of a voltage-dependent K+ channel in a lipid
membrane-like environment. Nature. 450, 376-382, 2007.
Sachyani D, Dvir M, Strulovich R, Tria G, Tobelaim W, Peretz A, Pongs O, Svergun D, Attali B, Hirsch JA.
Structural basis of a Kv7.1 potassium channel gating module: studies of the intracellular c-terminal
domain in complex with calmodulin. Structure. 22, 1582-1594, 2014.

26 | CBAC Center Heartbeat